Michael Gelband’s Gladstone Commercial Corp GOOD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-132,521
Closed -$1.41M 1761
2025
Q4
$1.41M Buy
132,521
+43,263
+48% +$481K 0.01% 878
2025
Q3
$1.1M Buy
89,258
+17,025
+24% +$227K 0.01% 935
2025
Q2
$1.03M Buy
72,233
+30,083
+71% +$427K 0.01% 954
2025
Q1
$631K Buy
+42,150
New +$665K 0.01% 1057
2024
Q4
Sell
-49,366
Closed -$802K 1713
2024
Q3
$802K Buy
+49,366
New +$741K ﹤0.01% 1037
2022
Q3
Sell
-24,972
Closed -$470K 2042
2022
Q2
$470K Sell
24,972
-21,985
-47% -$447K 0.01% 1388
2022
Q1
$1.03M Buy
46,957
+31,198
+198% +$701K 0.01% 1124
2021
Q4
$406K Buy
15,759
+2,172
+16% +$49.3K ﹤0.01% 1528
2021
Q3
$286K Buy
+13,587
New +$305K ﹤0.01% 1631
2021
Q1
Sell
-18,648
Closed -$336K 2289
2020
Q4
$336K Sell
18,648
-28,555
-60% -$504K ﹤0.01% 1479
2020
Q3
$795K Buy
47,203
+36,643
+347% +$668K 0.02% 785
2020
Q2
$198K Buy
+10,560
New +$173K 0.01% 1521
2020
Q1
Sell
-21,061
Closed -$460K 1290
2019
Q4
$460K Buy
+21,061
New +$478K 0.01% 902

Other funds holding GOOD

Michael Gelband's GOOD Position: Q1 2026 in Review

Michael Gelband sold out of Gladstone Commercial Corp (GOOD) in Q1 2026, closing a stake of 132,521 shares — an estimated $1.41M sold.

Michael Gelband first reported a position in GOOD in Q4 2019 and held it in 13 quarters. The position peaked at $1.41M in Q4 2025. 204 funds tracked by Wall St. Rank hold GOOD as of Q1 2026.

  • Michael Gelband reported no remaining Gladstone Commercial Corp position as of Q1 2026 after selling out during the quarter.
  • Michael Gelband sold 132,521 Gladstone Commercial Corp shares in Q1 2026, an estimated $1.41M.
  • Michael Gelband first reported a position in Gladstone Commercial Corp in Q4 2019 and held it in 13 quarters.
  • Michael Gelband's Gladstone Commercial Corp position peaked at $1.41M in Q4 2025.
  • 204 funds tracked by Wall St. Rank held Gladstone Commercial Corp as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.